Cuorips

Cuorips ROA

The Return on Assets (ROA) of Cuorips (4894.T) as of Oct 23, 2026 is -19.96 %. In the previous year, Return on Assets (ROA) was -11.22 % — a change of 77.87% (lower).

ROA

-19.96 %

YoY

77.87%

Last updated:

In 2026, Cuorips's return on assets (ROA) was -19.96 %, a 77.87% increase from the -11.22 % ROA in the previous year.

The Cuorips ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2021
-7.05 JPY
Jan 1, 2022
-9.28 JPY
Jan 1, 2023
-12.60 JPY
Jan 1, 2024
-10.22 JPY
Jan 1, 2025
-11.22 JPY
Jan 1, 2026
-19.96 JPY
The Cuorips ROA history
YEARROAYoY
-19.96 %+77.87%
-11.22 %+9.79%
-10.22 %-18.89%
-12.60 %+35.81%
-9.28 %+31.56%
-7.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cuorips Stock analysis

What does Cuorips do? Cuorips Inc generates revenue through regenerative medical products, primarily human iPS cell-derived cardiomyocyte sheets, and its CDMO business. The company develops these products in-house and through joint research with universities, research institutions, and major pharmaceutical companies. The CDMO services utilize CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept. Customers include major pharmaceutical companies and research institutions seeking regenerative medical solutions for the heart and other areas. The firm's regenerative medical products target heart conditions, developed through internal research and collaborations. The CDMO business provides contract development and manufacturing services using CLiC-1, serving pharmaceutical companies and research organizations. Revenue streams are derived from product sales and CDMO contracts, with the company focusing on heart-related applications and expanding into other medical areas through partnerships. Cuorips Inc's business model centers on leveraging its proprietary technology in iPS cell-derived cardiomyocyte sheets and CLiC-1 facility to serve pharmaceutical and research sectors. The company's products and services are designed for regenerative medicine applications, particularly for cardiac treatments, with sales and contracts driven by partnerships with major pharmaceutical companies and research institutions. Cuorips is one of the most popular companies on Eulerpool.

ROA Details

Understanding Cuorips's Return on Assets (ROA)

Cuorips's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Cuorips's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Cuorips's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Cuorips’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Cuorips stock

Return on Assets (ROA) of Cuorips is -19.96 % in 2026.

Return on Assets (ROA) of Cuorips changed from -11.22 % to -19.96 %, representing a 77.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Cuorips since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Cuorips with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cuorips

All Key Metrics — Cuorips